You are here

Danusertib, a Multi-Kinase Aurora Inhibitor, Promising for Treatment of CML Refractory to First- and Second-generation Kinase In

sandy craine's picture
Submitted by sandy craine on Tue, 12/01/2010 - 12:14pm
Cancer News Article Danusertib, a Multi-Kinase Aurora Inhibitor, Promising for Treatment of CML Refractory to First- and Second-generation Kinase Inhibitors Researchers involved in an international multicenter Phase I study have reported that danusertib (PHA-739358) produces responses in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who have failed treatment with Gleevec® (imatinib), Sprycel® (dasatinib), and Tasigna® (nilotinib). The details of this study were presented at the 2009 meeting of the American Society of Hematology (ASH) in New Orleans in early December.[1]

Cancer News Article

Danusertib, a Multi-Kinase Aurora Inhibitor, Promising for Treatment of CML Refractory to First- and Second-generation Kinase Inhibitors
Researchers involved in an international multicenter Phase I study have reported that danusertib (PHA-739358) produces responses in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who have failed treatment with Gleevec® (imatinib), Sprycel® (dasatinib), and Tasigna® (nilotinib). The details of this study were presented at the 2009 meeting of the American Society of Hematology (ASH) in New Orleans in early December.[1]

BBC News regarding NICE appraisal of dasatinib and nilotinib- plus TV3 interview regarding tasigna

sandy craine's picture
Submitted by sandy craine on Wed, 06/01/2010 - 11:40am
BBC News regarding NICE appraisal of dasatinib and nilotinib http://news.bbc.co.uk/1/hi/england/london/8440877.stm

BBC News regarding NICE appraisal of dasatinib and nilotinib
http://news.bbc.co.uk/1/hi/england/london/8440877.stm

Journal of Clinical Oncology Editorial: CML Reversing the Chronic Phase

sandy craine's picture
Submitted by sandy craine on Mon, 04/01/2010 - 1:16pm
JOURNAL OF CLINICAL ONCOLOGY EDITORIAL Chronic Myeloid Leukemia: Reversing the Chronic Phase John M. Goldman, Imperial College London, London, United Kingdom

JOURNAL OF CLINICAL ONCOLOGY
EDITORIAL

Chronic Myeloid Leukemia: Reversing the Chronic Phase
John M. Goldman, Imperial College London, London, United Kingdom

Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

sandy craine's picture
Submitted by sandy craine on Mon, 04/01/2010 - 11:54am
Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia J Clin Oncol. 2009 Dec 14; Epub online ahead of print, JE Cortes , D Jones, S O'Brien, E Jabbour, F Ravandi, C Koller, G Borthakur, B Walker, W Zhao, J Shan, H Kantarjian

Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
J Clin Oncol. 2009 Dec 14; Epub online ahead of print, JE Cortes , D Jones, S O'Brien, E Jabbour, F Ravandi, C Koller, G Borthakur, B Walker, W Zhao, J Shan, H Kantarjian

From Gleevec to Tasigna: Novartis' Switch Push Kicks Off With Front-Line CML

sandy craine's picture
Submitted by sandy craine on Mon, 04/01/2010 - 11:45am
From Gleevec to Tasigna: Novartis' Switch Push Kicks Off With Front-Line CML Submission The Pink Sheet Daily. 2009 Dec 9, J Merrill

From Gleevec to Tasigna: Novartis' Switch Push Kicks Off With Front-Line CML Submission
The Pink Sheet Daily. 2009 Dec 9, J Merrill

Best of ASH Abstracts 2009- compiled by Jan Geissler

sandy craine's picture
Submitted by sandy craine on Fri, 18/12/2009 - 11:23am
This is a compilation of the best/most relevant abstract presented at ASH conference this year. It was written by my friend and CML colleague, Jan Geissler, Director of leukemie-online.de

This is a compilation of the best/most relevant abstract presented at ASH conference this year. It was written by my friend and CML colleague, Jan Geissler, Director of leukemie-online.de

Pages